Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
CNCE Concert Pharmaceuticals, Inc. daily Stock Chart
CNCE [NASD]
Concert Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-3.33 Insider Own2.90% Shs Outstand30.04M Perf Week-2.25%
Market Cap326.53M Forward P/E- EPS next Y-3.55 Insider Trans1.28% Shs Float24.89M Perf Month11.83%
Income-78.50M PEG- EPS next Q-0.79 Inst Own53.00% Short Float2.49% Perf Quarter56.97%
Sales1.10M P/S296.85 EPS this Y-159.00% Inst Trans-0.62% Short Ratio3.06 Perf Half Y5.84%
Book/sh5.01 P/B2.17 EPS next Y-10.20% ROA-45.20% Target Price21.00 Perf Year-23.67%
Cash/sh4.23 P/C2.57 EPS next 5Y- ROE-55.10% 52W Range5.36 - 17.83 Perf YTD17.83%
Dividend- P/FCF- EPS past 5Y-33.00% ROI-33.30% 52W High-38.11% Beta1.00
Dividend %- Quick Ratio9.50 Sales past 5Y-16.20% Gross Margin- 52W Low105.88% ATR0.75
Employees71 Current Ratio9.50 Sales Q/Q-9.10% Oper. Margin- RSI (14)53.19 Volatility5.46% 8.35%
OptionableYes Debt/Eq0.00 EPS Q/Q2.80% Profit Margin- Rel Volume0.41 Prev Close10.87
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 BMO Payout- Avg Volume202.46K Price11.03
Recom2.00 SMA20-0.62% SMA5012.25% SMA20015.80% Volume82,137 Change1.52%
Oct-03-19Reiterated H.C. Wainwright Buy $29 → $25
Jun-24-19Initiated SunTrust Buy $30
Jun-13-19Upgrade Janney Neutral → Buy
Jun-13-19Reiterated H.C. Wainwright Buy $26 → $29
Sep-13-18Initiated Janney Neutral
Mar-09-18Upgrade Mizuho Neutral → Buy $23 → $27
Jan-12-18Downgrade Mizuho Buy → Neutral $23
Oct-26-17Initiated Mizuho Buy $23
Jul-24-17Initiated H.C. Wainwright Buy $20
Mar-07-17Reiterated Stifel Buy $21 → $31
Jul-01-16Initiated Stifel Buy $23
Sep-22-15Reiterated ROTH Capital Buy $22 → $32
Aug-12-15Initiated Brean Capital Buy $21
Nov-12-14Reiterated ROTH Capital Buy $28 → $21
Mar-10-14Initiated UBS Buy $25
Jan-30-20 04:01PM  Concert Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jan-28-20 09:00AM  Concert Pharmaceuticals Announces Pricing of Public Offering Business Wire +9.83%
Jan-27-20 04:02PM  Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire -8.61%
04:01PM  Concert Pharmaceuticals Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543 Business Wire
Jan-24-20 05:52AM  Should You Be Concerned About Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) Historical Volatility? Simply Wall St. -15.00%
Jan-22-20 08:40AM  Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata Business Wire +33.03%
Dec-19-19 04:05PM  Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata Business Wire
Dec-16-19 05:54AM  We Think Concert Pharmaceuticals (NASDAQ:CNCE) Needs To Drive Business Growth Carefully Simply Wall St.
Dec-13-19 02:18PM  Do Hedge Funds Love Concert Pharmaceuticals Inc (CNCE)? Insider Monkey
Dec-02-19 07:00AM  Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia Business Wire
Nov-25-19 11:21PM  Edited Transcript of CNCE earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 07:00AM  Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire +6.63%
Nov-10-19 08:40AM  Should You Worry About Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Salary Level? Simply Wall St.
Nov-07-19 08:15AM  Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:00AM  Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update Business Wire
Nov-06-19 07:00AM  Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia Business Wire
Nov-05-19 01:36PM  Concert Pharmaceuticals Inc (CNCE) Is Burning These Hedge Funds Insider Monkey
Oct-31-19 10:35AM  Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for Zacks
07:00AM  Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019 Business Wire
Oct-12-19 03:15AM  Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress Business Wire
Oct-02-19 07:00AM  Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference Business Wire
Sep-27-19 11:48AM  Concert stock falls 36 percent on Alzheimer's drug trial failure American City Business Journals -36.68%
Sep-23-19 07:00AM  Concert Pharmaceuticals Names Jeffrey Munsie as Chief Legal Officer Business Wire
Sep-19-19 10:32AM  Did You Manage To Avoid Concert Pharmaceuticals's (NASDAQ:CNCE) 20% Share Price Drop? Simply Wall St.
Sep-17-19 07:00AM  Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata Business Wire
Sep-12-19 07:00AM  Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress Business Wire
Aug-29-19 07:00AM  Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Aug-27-19 12:17AM  Edited Transcript of CNCE earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-16-19 03:10PM  What You Must Know About Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) Beta Value Simply Wall St.
Aug-06-19 05:12AM  Concert Pharmaceuticals, Inc. (CNCE) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 09:25AM  Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates Zacks +8.75%
Jul-25-19 07:00AM  Concert Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 1, 2019 Business Wire
Jul-05-19 03:12PM  Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Increased Their Holdings Simply Wall St.
Jun-13-19 05:05PM  Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I Zacks +6.47%
Jun-12-19 07:00AM  Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers Business Wire
Jun-05-19 07:00AM  Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata Business Wire
May-28-19 02:13PM  Edited Transcript of CNCE earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-16-19 07:00AM  Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata Business Wire
May-14-19 07:00AM  Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
May-07-19 01:51PM  Why Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Pay Matters To You Simply Wall St.
May-02-19 11:52AM  Concert Pharmaceuticals, Inc. (CNCE) Q1 2019 Earnings Call Transcript Motley Fool
08:01AM  Concert: 1Q Earnings Snapshot Associated Press
07:00AM  Concert Pharmaceuticals Reports First Quarter 2019 Financial Results Business Wire
Apr-29-19 07:00AM  Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors Business Wire
Apr-25-19 10:34AM  Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline Zacks
07:00AM  Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019 Business Wire
Apr-11-19 09:46AM  Concert Pharma Initiates Early-Stage Schizophrenia Study Zacks
07:00AM  Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting Business Wire
Apr-10-19 06:30AM  Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia Business Wire
Apr-08-19 03:09PM  Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling MarketWatch -15.71%
02:45PM  Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding Business Wire
Mar-25-19 10:42AM  New Strong Sell Stocks for March 25th Zacks -7.41%
Mar-12-19 08:13AM  New Strong Sell Stocks for March 12th Zacks
07:00AM  Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference Business Wire
Mar-07-19 08:40AM  Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed Zacks
Mar-06-19 07:00AM  Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata Business Wire
Mar-05-19 04:09PM  Edited Transcript of CNCE earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents +5.42%
Mar-01-19 07:00AM  Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting Business Wire
Feb-28-19 10:49AM  Concert Pharmaceuticals, Inc. (CNCE) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Concert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical Programs Business Wire
Feb-21-19 07:00AM  Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019 Business Wire
Feb-13-19 07:36AM  Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Time For A Financial Health Check Simply Wall St.
Feb-12-19 08:00AM  Analysis: Positioning to Benefit within Masco, Ascena Retail Group, Leidos, NetScout, MYR Group, and Concert Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-11-19 07:00AM  Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting Business Wire
Feb-05-19 02:25PM  Mizuho's 9 Best Biotech Stocks to Buy for 2019 Kiplinger
Jan-24-19 07:00AM  Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia Business Wire
Jan-22-19 07:00AM  Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata Business Wire
Jan-02-19 08:55AM  How Much Are Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Spending On Buying Shares? Simply Wall St. +8.13%
Dec-19-18 11:39PM  Do Hedge Funds Love Concert Pharmaceuticals Inc (CNCE)? Insider Monkey
Dec-17-18 07:00AM  Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia Business Wire
Nov-28-18 08:41AM  Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed Zacks +9.71%
Nov-26-18 11:36AM  Should You Be Concerned About Concert Pharmaceuticals Incs (NASDAQ:CNCE) Historical Volatility? Simply Wall St.
Nov-12-18 08:45AM  Report: Exploring Fundamental Drivers Behind Sterling Construction, Tredegar, j2 Global, Medical Transcription Billing, Concert Pharmaceuticals, and Senseonics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -21.61%
07:00AM  Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata Business Wire
Nov-07-18 07:00AM  Concert Pharmaceuticals to Participate at Upcoming Investor Conferences Business Wire
Nov-06-18 03:25PM  Edited Transcript of CNCE earnings conference call or presentation 1-Nov-18 12:30pm GMT Thomson Reuters StreetEvents
Nov-05-18 04:01PM  Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine Business Wire +11.69%
Nov-01-18 08:38AM  Concert: 3Q Earnings Snapshot Associated Press
07:00AM  Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update Business Wire
Oct-25-18 07:00AM  Concert Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 1, 2018 Business Wire +6.18%
Oct-12-18 09:15AM  Detailed Research: Economic Perspectives on Graco, Immunomedics, Concert Pharmaceuticals, Macquarie Infrastructure, Systemax, and Service Corporation International What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-10-18 01:56PM  What is Behind Concert Pharmaceuticals Incs (NASDAQ:CNCE) Superior ROE? Simply Wall St.
Sep-26-18 07:00AM  Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata Business Wire +5.14%
Aug-29-18 07:00AM  Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Aug-09-18 06:35AM  Inside Concert Pharma's new HQ in popular Lexington biotech campus American City Business Journals
Aug-07-18 08:30AM  Consolidated Research: 2018 Summary Expectations for Independent Bank Group, Concert Pharmaceuticals, Bank of Marin, Eclipse Resources, MKS Instruments, and Container Store Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-05-18 11:18PM  Edited Transcript of CNCE earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 11:10AM  Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates Zacks +8.75%
10:06AM  Concert: 2Q Earnings Snapshot Associated Press
07:00AM  Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Company Update Business Wire
Jul-26-18 07:00AM  Concert Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018 Business Wire
May-09-18 01:46PM  Edited Transcript of CNCE earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-03-18 08:27AM  Concert: 1Q Earnings Snapshot Associated Press +7.13%
07:00AM  Concert Pharmaceuticals Reports First Quarter 2018 Financial Results Business Wire
Apr-27-18 07:30AM  Wired News Concert Pharma Enrolled Last Patient in Phase-2a Trial Evaluating CTP-543 in Alopecia Areata ACCESSWIRE
Apr-26-18 07:00AM  Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor Conferences Business Wire
Apr-25-18 07:00AM  Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata Business Wire
Apr-23-18 07:35AM  Research Report Identifies Signature Bank, Concert Pharmaceuticals, Easterly Government Properties, Hilltop, Columbia Banking System, and New Jersey Resources with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-06-18 04:11PM  Edited Transcript of CNCE earnings conference call or presentation 1-Mar-18 1:30pm GMT Thomson Reuters StreetEvents
07:00AM  Concert Pharmaceuticals Present at Upcoming Investor Conferences Business Wire
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Auchincloss Thomas GDirectorFeb 03Buy10.911,00010,9105,000Feb 04 11:30 AM
Stuart NancyChief Operating OfficerDec 04Option Exercise4.415,89626,001104,739Dec 06 04:05 PM
Tung Roger DChief Executive OfficerDec 04Option Exercise4.4113,16658,062644,686Dec 06 04:05 PM
van Heek ChristiDirectorOct 08Buy5.905,00029,50410,000Oct 10 08:58 AM
HUTT PETER BARTONDirectorAug 08Option Exercise4.413,53915,6077,963Aug 12 04:00 PM
HUTT PETER BARTONDirectorAug 08Sale10.313,53936,4874,424Aug 12 04:00 PM
van Heek ChristiDirectorAug 02Buy10.845,00054,2035,000Oct 10 08:58 AM
BVF PARTNERS L P/IL10% OwnerJun 10Sale10.70386,2894,134,799169,589Jun 12 04:16 PM
Tung Roger DChief Executive OfficerApr 23Option Exercise3.7914,60155,338631,520Apr 24 04:27 PM
Tung Roger DChief Executive OfficerApr 10Option Exercise4.4124,886109,747616,919Apr 10 04:34 PM
open in yahoo | open in reuters | open in google